RETATRUTIDE

:root{--ink:#16202a;--muted:#5c6975;--line:#dce3e8;--panel:#f6f8fa;--warning-bg:#fff8e8;--danger-bg:#fff0f0} *{box-sizing:border-box} bo

TB-500

SELANK

MAZDUTIDE

Retatrutide (LY3437943): What It Is, How It Works, Benefits, and Research Overview

A comprehensive, evidence-graded review of retatrutide, an investigational once-weekly peptide that activates the GIP, GLP-1, and glucagon receptors and has produced phase 3 weight-loss results approaching those historically associated with bariatric surgery.

Research and medical notice: Retatrutide remains investigational and is not FDA approved or approved by any other regulatory agency as of July 14, 2026. Lilly states that it is legally available only through company-sponsored clinical trials. Products sold online as “retatrutide” are not authorized clinical products and cannot be assumed authentic, sterile, correctly dosed, or safe.

Terminology correction: Retatrutide is sometimes marketed online as “GLP-3.” That term is scientifically inaccurate. Retatrutide is a triple hormone-receptor agonist acting at GIPR, GLP-1R, and GCGR; there is no recognized “GLP-3 receptor” involved.

What Is Retatrutide?

Retatrutide, development code LY3437943, is a synthetic, long-acting, single-chain peptide designed to activate three metabolic hormone receptors:

GIP receptor for insulinotropic, adipose, and metabolic signaling
GLP-1 receptor for appetite reduction, satiety, glucose-dependent insulin secretion, and gastric regulation
Glucagon receptor for energy expenditure, substrate mobilization, fat oxidation, and liver metabolism

Development code
LY3437943

Drug type
Long-acting acylated peptide

Primary receptors
GIPR + GLP-1R + GCGR

Route studied
Once-weekly subcutaneous injection

Phase 3 maximum result
28.3% at 80 weeks

FDA approval
No

🧬 Structure, Sequence, and Molecular Properties

Peptide design

Retatrutide is a chemically modified single-chain peptide derived from incretin and glucagon-family hormone sequences. It includes noncanonical amino-acid substitutions and a fatty-acid side chain that supports albumin binding and once-weekly exposure.

Public sequence representation

Public chemical databases and patent-derived records describe a 39-residue peptide with a lysine-linked hydrophilic spacer and long-chain fatty-acid modification. Sequence notation varies because some records include the linker and lipid as separate structural components.

YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS-NH₂

Sequence notation warning: “X” positions indicate noncanonical amino-acid residues or chemically modified positions. Vendor shorthand may omit the exact spacer, lipid-chain composition, attachment site, terminal chemistry, or counterion. An authenticated sponsor or pharmacopoeial reference should control identity testing.

Public molecular-property records

Peptide length	Commonly represented as 39 amino-acid residues
PubChem classification	Triple peptide agonist at GCGR, GIPR, and GLP-1R
Representative molecular formula	C₂₂₁H₃₄₂N₄₆O₆₈ for a public sodium-salt record
Free-form molecular weight	Approximately 4.7 kDa; exact value depends on structural and salt representation
Long-acting feature	Fatty-acid acylation and albumin association
Disulfide bridge	None required in the commonly represented linear structure

Why reference forms differ

Large modified peptides may be represented as neutral forms, sodium salts, hydrates, or counterion-containing drug substances. A COA must state which form and exact molecular definition were used.

📅 Discovery and Development Timeline

Lilly discovery program

Lilly developed retatrutide as a single molecule capable of balancing GIP, GLP-1, and glucagon receptor activity.

2022: Phase 2 type 2 diabetes results

Early trials showed strong A1C and body-weight reductions in adults with type 2 diabetes.

2023: Phase 2 obesity publication

A 48-week randomized trial showed up to 24.2% mean weight reduction at the 12 mg dose.

2023: TRIUMPH phase 3 program begins

Lilly launched registrational trials in obesity, knee osteoarthritis, sleep apnea, diabetes, cardiovascular disease, kidney disease, and liver disease.

December 2025: TRIUMPH-4

Lilly reported substantial weight loss together with improvement in knee osteoarthritis pain.

March–June 2026: TRANSCEND-T2D-1

Phase 3 diabetes results demonstrated significant A1C and weight reductions and were presented and published in June 2026.

May 21, 2026: TRIUMPH-1 topline result

Lilly reported 28.3% mean weight loss at 80 weeks with 12 mg retatrutide.

June 2026: Broader complication data

Additional findings were presented for knee osteoarthritis pain, obstructive sleep apnea, and type 2 diabetes.

Current status

Retatrutide remains unapproved. Lilly has stated that regulatory submission depends on completion of the phase 3 program.

🧠 How Does Retatrutide Work?

Retatrutide activates GIPR + GLP-1R + GCGR → reduced appetite and calorie intake + improved insulin and glucose signaling + increased energy expenditure and fat oxidation → major weight reduction and cardiometabolic improvement

1. GLP-1 receptor signaling

GLP-1 receptor activation reduces hunger, promotes fullness, enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release during hyperglycemia, and slows gastric emptying.

2. GIP receptor signaling

GIP receptor activation supports glucose-dependent insulin release and may influence adipose-tissue function, nutrient handling, nausea balance, and metabolic flexibility.

3. Glucagon receptor signaling

Glucagon receptor activation may increase energy expenditure, mobilize stored fat, increase hepatic substrate turnover, and reduce liver fat.

4. Triple-receptor synergy

The central development hypothesis is that GIP and GLP-1 activity can control appetite and glucose while glucagon contributes additional energy expenditure and fat oxidation.

🎯 Triple-Receptor Profile

Target	Action	Potential contribution
GIP receptor	Direct agonist	Insulin secretion, metabolic flexibility, adipose signaling
GLP-1 receptor	Direct agonist	Appetite, satiety, glucose regulation, gastric emptying
Glucagon receptor	Direct agonist	Energy expenditure, fat oxidation, liver metabolism
cAMP signaling	Primary downstream pathway at all three receptors	Functional potency and receptor balance
Albumin	Reversible association through acylation	Extended exposure and weekly dosing

Receptor-balance importance

A correct retatrutide preparation must reproduce the intended potency at all three receptors. A peptide can have the correct nominal mass but the wrong receptor balance because of sequence errors, epimerization, incorrect lipidation, oxidation, or aggregation.

Phase 2 Obesity Evidence

Trial design

The phase 2 trial enrolled 338 adults with obesity or overweight and at least one weight-related condition, without diabetes. Participants received placebo or multiple retatrutide doses for 48 weeks.

Outcome	Highest-dose result
Mean weight reduction at 24 weeks	Up to 17.5%
Mean weight reduction at 48 weeks	Up to 24.2%
Participants losing at least 15%	High proportion in the upper-dose groups
Participants losing at least 20%	More than half in the 12 mg group

No clear plateau

Weight loss had not clearly plateaued at 48 weeks in the highest-dose group.

Cardiometabolic effects

Waist circumference, blood pressure, lipids, glucose measures, and liver-fat markers improved.

TRIUMPH-1 Phase 3 Evidence

Trial design

TRIUMPH-1 randomized 2,339 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes, to 4 mg, 9 mg, 12 mg, or placebo for 80 weeks.

Group	Average weight change at 80 weeks	Average pounds lost
Retatrutide 4 mg	−19.0%	47.2 lb
Retatrutide 9 mg	−25.9%	64.4 lb
Retatrutide 12 mg	−28.3%	70.3 lb
Placebo	−2.2%	5.5 lb

High-threshold responders

Weight-loss threshold	12 mg retatrutide	Placebo
At least 25%	62.5%	2.2%
At least 30%	45.3%	0.5%
At least 35%	27.2%	0.3%

Waist circumference

The 12 mg group lost an average of 24.1 cm, or approximately 9.5 inches, from waist circumference.

Cardiometabolic effects

Improvements were reported in triglycerides, non-HDL cholesterol, systolic blood pressure, waist circumference, and high-sensitivity C-reactive protein.

104-Week Extension Findings

Extension population

A prespecified extension enrolled 532 participants with baseline BMI of at least 35 who completed the main study and tolerated therapy.

Extension group	Average weight change at 104 weeks
4 mg to maximum tolerated dose	−27.9%
9 mg to maximum tolerated dose	−29.5%
12 mg to maximum tolerated dose	−30.3%

Interpretation

Participants with severe obesity continued to lose weight beyond 80 weeks, with average reductions reaching approximately 30%.

Selection limitation

The extension included participants who completed the main study and tolerated medication, so it should not be interpreted as the expected result for every treated patient.

Type 2 Diabetes Evidence

Phase 2

Retatrutide produced substantial A1C and weight reductions in adults with type 2 diabetes, supporting phase 3 development.

TRANSCEND-T2D-1

Phase 3 results announced and published in 2026 showed significant reductions in A1C and body weight among adults inadequately controlled with diet and exercise.

Glucose-dependent effects

GIP and GLP-1 activity increase insulin secretion primarily when glucose is elevated, while the molecule’s overall balance offsets glucagon-related glucose pressure.

Hypoglycemia

Risk depends strongly on background therapy and is expected to increase with insulin or insulin secretagogues.

Osteoarthritis, Sleep Apnea, and Other Complications

Knee osteoarthritis

TRIUMPH-4 reported substantial weight loss and meaningful improvement in knee osteoarthritis pain.

Obstructive sleep apnea

TRIUMPH-1 included a basket study evaluating moderate-to-severe obstructive sleep apnea in adults with obesity.

Chronic low back pain

Additional trials are evaluating pain and functional outcomes in adults with obesity.

Cardiovascular and renal outcomes

Large trials are studying whether risk-factor improvements translate into fewer cardiovascular and kidney events.

MASLD

Retatrutide is being evaluated for metabolic dysfunction-associated steatotic liver disease and related hepatic outcomes.

Body Composition, Liver Fat, and Cardiometabolic Effects

Fat mass

Weight reduction is driven largely by fat-mass loss, although lean tissue also declines with major weight reduction.

Visceral fat

Large waist reductions suggest major decreases in central and visceral adiposity.

Liver fat

Phase 2 imaging analyses found large liver-fat reductions, including resolution of steatosis in many participants.

Blood pressure and lipids

Phase 2 and phase 3 programs reported reductions in systolic blood pressure, triglycerides, and non-HDL cholesterol.

Inflammation

High-sensitivity C-reactive protein improved in TRIUMPH-1.

No outcomes approval yet

Improved risk markers do not prove reduced heart attack, stroke, kidney failure, or mortality until dedicated outcome trials are completed.

Side Effects and Safety Considerations

Most common phase 3 adverse effects

Nausea
Diarrhea
Constipation
Vomiting
Reduced appetite
Upper respiratory tract infection

Dysesthesia

Abnormal skin sensations were reported in 5.1%, 12.3%, and 12.5% of participants receiving 4 mg, 9 mg, and 12 mg, compared with 0.9% on placebo. Most events were mild to moderate and resolved during treatment.

Urinary tract infections

UTIs occurred somewhat more often in retatrutide groups than with placebo in TRIUMPH-1.

Discontinuation due to adverse events

Rates were 4.1%, 6.9%, and 11.3% with 4 mg, 9 mg, and 12 mg, compared with 4.9% on placebo.

Potential incretin-class risks

Pancreatitis
Gallbladder disease
Dehydration and kidney injury
Severe gastrointestinal intolerance
Delayed gastric emptying
Hypoglycemia with insulin or secretagogues
Loss of lean tissue

Glucagon-related considerations

Potential concerns include increased heart rate, hepatic glucose output, altered amino-acid metabolism, and changes in liver or lipid metabolism.

Long-term uncertainty

Rare adverse effects, cardiovascular outcomes, kidney outcomes, cancer risk, pancreatic safety, gallbladder risk, and weight regain after stopping remain under study.

Pharmacokinetics and Weekly Dosing

Albumin association

The fatty-acid side chain promotes reversible albumin binding and reduces renal clearance.

Protease resistance

Noncanonical residues and sequence engineering reduce rapid enzymatic degradation.

Once-weekly administration

The molecule is studied as a once-weekly subcutaneous injection.

Phase 3 escalation

TRIUMPH-1 began at 2 mg and increased every four weeks to target doses of 4 mg, 9 mg, or 12 mg.

No approved dosing schedule

These research schedules are not prescribing instructions because retatrutide remains unapproved.

Regulatory Status

United States

Retatrutide is not FDA approved.

Worldwide

Lilly states that retatrutide has not been approved by any regulatory agency.

Legal availability

It is legally available only to participants in Lilly-sponsored clinical trials.

Online products

Lilly warns that products sold to consumers may contain the wrong ingredient, unknown impurities, contaminants, or incorrect amounts.

Potential submission

Lilly has indicated that a regulatory filing could follow completion of the remaining pivotal trials.

🧪 Laboratory Testing Methods

Method	Purpose	Important limitation
RP-HPLC / UPLC	Separates intact retatrutide from deletion peptides, deacylated material, oxidation products, and aggregates.	Area purity alone does not prove identity or receptor balance.
LC-HRMS	Confirms intact molecular mass against the exact reference form.	Salt and structural representations can change reported mass.
MS/MS peptide mapping	Confirms sequence, noncanonical residues, linker, and lipidation site.	Requires an authenticated sponsor-equivalent standard.
Amino-acid analysis	Confirms composition and supports net peptide content.	Does not prove residue order or modification location.
Chiral amino-acid analysis	Detects epimerization and incorrect stereochemistry.	Hydrolysis can introduce artifacts.
Linker and fatty-acid analysis	Confirms spacer, lipid-chain identity, and attachment site.	Vendor shorthand may omit structural detail.
Deacylated-peptide assay	Measures loss or absence of the long-acting side chain.	Deacylated material can retain partial receptor activity.
Oxidation and deamidation assays	Measure chemically altered degradants.	Some variants require high-resolution separation.
SEC-HPLC	Measures aggregates and high-molecular-weight species.	Small reversible oligomers may require orthogonal testing.
Net peptide-content assay	Measures actual active peptide mass.	Must correct for water, counterions, and excipients.
GIPR cAMP assay	Measures GIP receptor potency.	Does not establish GLP-1R or GCGR potency.
GLP-1R cAMP assay	Measures GLP-1 receptor potency.	Must use comparable receptor-expression systems.
GCGR cAMP assay	Measures glucagon receptor potency.	Receptor density affects EC50.
Triple-receptor potency ratio	Confirms intended pharmacological balance.	No universal cross-laboratory ratio exists.
Albumin-binding assay	Confirms long-acting design.	Does not fully predict human half-life.
Plasma stability	Measures proteolysis and deacylation.	Species differences are important.
Residual-solvent and counterion testing	Measures synthesis solvents, TFA, acetate, and salts.	Does not establish biological potency.
Sterility and endotoxin	Required for finished injectable products.	Raw-peptide purity cannot establish injectable safety.
Particulate matter	Measures visible and subvisible particles.	Requires final-product testing.
Stability-indicating assay	Tracks oxidation, deamidation, hydrolysis, aggregation, deacylation, and potency loss.	Requires validated forced-degradation studies.

📄 How to Interpret a Retatrutide COA

Identify the exact structural form: Neutral peptide, sodium salt, counterion-containing material, or another representation.
Verify the complete peptide sequence and every noncanonical residue.
Confirm the linker, fatty-acid chain, and exact attachment site.
Use LC-HRMS plus MS/MS peptide mapping.
Confirm stereochemistry: Epimers can share the same nominal mass.
Measure deletion peptides, deacylated material, oxidation, deamidation, hydrolysis, and aggregates.
Report net peptide content: “99% HPLC purity” is not the actual number of milligrams.
Test GIPR, GLP-1R, and GCGR potency separately.
Confirm the triple-receptor potency ratio.
Confirm albumin binding and plasma stability.
For injectable products, require sterility, endotoxin, particles, fill accuracy, container closure, and stability.
Do not infer Lilly equivalence: A vendor COA cannot prove equivalence to Lilly’s clinical-trial drug.

📊 Retatrutide vs Semaglutide vs Tirzepatide vs Survodutide

Feature	Retatrutide	Semaglutide	Tirzepatide	Survodutide
Receptors	GIPR + GLP-1R + GCGR	GLP-1R	GIPR + GLP-1R	GCGR + GLP-1R
Route	Weekly injection	Weekly injection	Weekly injection	Weekly injection
Maximum reported phase 3 mean loss	28.3% at 80 weeks	Lower in pivotal obesity trials	Lower in pivotal obesity trials	16.6% in SYNCHRONIZE-1
FDA approved?	No	Yes, specific products	Yes, specific products	No

Retatrutide vs Mazdutide vs Pemvidutide

Compound	Receptors	Status
Retatrutide	GIPR + GLP-1R + GCGR	Phase 3, unapproved
Mazdutide	GLP-1R + GCGR	Approved in China
Pemvidutide	GLP-1R + GCGR	Investigational

Retatrutide vs Bariatric Surgery

Feature	Retatrutide phase 3	Bariatric surgery
Average weight loss	Up to approximately 28–30% in selected analyses	Procedure dependent, often within a similar broad range
Intervention	Ongoing medication	Surgical anatomical and hormonal change
Evidence duration	Up to two years in current pivotal data	Long-term decades of outcome data
Main limitations	GI effects, dysesthesia, long-term uncertainty	Surgical risk, nutritional deficiencies, anatomy changes

Raw Retatrutide vs Lilly Clinical Drug Product

Quality attribute	Raw research material	Lilly clinical product
Identity	Vendor-dependent claim	Sponsor-controlled sequence and reference
Potency	Often not fully characterized	Validated triple-receptor release assays
Microbiology	May lack finished-product testing	Sterility, endotoxin, particles, validated fill
Exposure	Unknown	Supported by clinical PK
Clinical equivalence	Not established by COA	Defined by controlled manufacturing and trials

🖼️ Original Diagram Specifications

Diagram 1: Retatrutide peptide architecture

Show the 39-residue peptide, noncanonical amino acids, lysine modification site, hydrophilic linker, and fatty-acid side chain.

Diagram 2: Triple-receptor mechanism

Show GIPR, GLP-1R, and GCGR activation converging on appetite, glucose control, fat oxidation, and energy expenditure.

Diagram 3: TRIUMPH-1 results

Show 19.0%, 25.9%, and 28.3% weight reduction at 4 mg, 9 mg, and 12 mg versus 2.2% placebo.

Diagram 4: 104-week extension

Show average weight loss reaching 30.3% among selected participants with baseline BMI at least 35.

Diagram 5: Benefit–risk balance

Show extreme weight and metabolic benefits opposite gastrointestinal effects, dysesthesia, UTIs, and discontinuation.

Diagram 6: Triple agonist comparison

Compare semaglutide, tirzepatide, survodutide, mazdutide, and retatrutide by receptor targets.

Diagram 7: COA workflow

Show exact sequence, HRMS, peptide mapping, lipidation, chiral analysis, triple-receptor potency, albumin binding, sterility, and stability.

❓ Frequently Asked Questions

Is retatrutide a peptide?

Yes. It is a long-acting chemically modified peptide.

What is its development code?

LY3437943.

What receptors does it activate?

GIP, GLP-1, and glucagon receptors.

Is “GLP-3” the correct name?

No. Triple agonist is the scientifically correct description.

Is retatrutide FDA approved?

No.

Is it approved anywhere?

No regulatory agency had approved retatrutide as of July 14, 2026.

How much weight loss did phase 3 report?

TRIUMPH-1 reported 28.3% average loss at 80 weeks with 12 mg and 30.3% at 104 weeks in a selected high-BMI extension population.

How much weight loss occurred with 4 mg?

Approximately 19.0% at 80 weeks.

What are the most common side effects?

Nausea, diarrhea, constipation, vomiting, and reduced appetite.

What is dysesthesia?

An abnormal sensation such as tingling, burning, numbness, or altered skin sensitivity.

How is retatrutide different from tirzepatide?

Tirzepatide activates GIP and GLP-1 receptors; retatrutide also activates the glucagon receptor.

How is it different from survodutide?

Survodutide activates GLP-1 and glucagon receptors but not GIP receptors.

How is it administered in trials?

Once-weekly subcutaneous injection.

Can retatrutide be bought legally online?

No. Lilly states it is legally available only through Lilly-sponsored clinical trials.

Does 99% HPLC purity prove authentic retatrutide?

No. Exact sequence, noncanonical residues, lipidation, stereochemistry, net content, aggregates, sterility, and all three receptor potencies must be verified.

Final Thoughts

Retatrutide is an investigational triple hormone-receptor peptide with the strongest phase 3 average weight-loss result yet reported for a pharmacologic obesity treatment. TRIUMPH-1 found 28.3% average loss at 80 weeks with 12 mg, while a selected extension population with more severe obesity reached 30.3% at 104 weeks.

The triple mechanism is designed to combine GIP and GLP-1 control of appetite and glucose with glucagon-driven energy expenditure and fat oxidation. This may explain the unusually large reductions in body weight, waist circumference, liver fat, lipids, blood pressure, and inflammation markers.

Retatrutide remains unapproved, however, and long-term cardiovascular, renal, pancreatic, gallbladder, cancer, lean-mass, and weight-maintenance outcomes are not yet established. Gastrointestinal effects are common, dysesthesia is a distinctive safety signal, and discontinuation increases with dose.

Analytical authentication requires much more than an HPLC purity percentage. A credible evaluation must confirm the exact peptide sequence, noncanonical residues, spacer and lipid side chain, attachment site, stereochemistry, intact mass, impurity profile, net peptide content, GIPR potency, GLP-1R potency, GCGR potency, albumin binding, sterility, particles, and stability against an authenticated reference standard.

📚 References

Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023.
Eli Lilly and Company. Retatrutide delivered powerful weight loss in pivotal Phase 3 TRIUMPH-1 trial. May 21, 2026.
Eli Lilly and Company. What to know about retatrutide. Updated June 2026.
ClinicalTrials.gov. TRIUMPH-1, NCT05929066.
ClinicalTrials.gov. TRIUMPH-3, NCT05882045.
ClinicalTrials.gov. TRIUMPH-4, NCT05931367.
ClinicalTrials.gov. TRIUMPH-5, NCT05929079.
ClinicalTrials.gov. TRIUMPH-9, NCT07357415.
Lilly Clinical Trials. Retatrutide obesity maintenance study.
Rosenstock J, et al. Retatrutide in type 2 diabetes: phase 2 trial. Lancet. 2023.
Eli Lilly and Company. TRANSCEND-T2D-1 phase 3 results. March and June 2026.
Eli Lilly and Company. TRIUMPH-4 knee osteoarthritis topline results. December 2025.
PubChem. Retatrutide compound record.
PubChem. Retatrutide sodium-salt compound record.
Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist. Cell Metabolism. 2022.
Urva S, et al. Retatrutide pharmacokinetics and dose-response studies. Clinical Pharmacology.
Finan B, et al. Unimolecular dual and triple incretin receptor agonists. Science Translational Medicine.
Finan B, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine.
Day JW, et al. GLP-1/glucagon co-agonism and obesity. Nature Chemical Biology.
Pocai A, et al. GLP-1/glucagon receptor dual agonism reverses obesity. Diabetes.
Müller TD, et al. Glucagon-like peptide 1 molecular physiology and therapeutic applications. Nature Reviews Drug Discovery.
Holst JJ. The physiology of GLP-1. Physiological Reviews.
Campbell JE, Drucker DJ. Islet alpha cells and glucagon. Cell Metabolism.
Habegger KM, et al. The metabolic actions of glucagon revisited. Nature Reviews Endocrinology.
Baggio LL, Drucker DJ. Biology of incretins. Gastroenterology.
Nauck MA, Meier JJ. Incretin hormones and GLP-1 receptor agonists. Lancet Diabetes & Endocrinology.
Secher A, et al. The arcuate nucleus mediates GLP-1 receptor agonist weight loss. Journal of Clinical Investigation.
Gabery S, et al. Semaglutide lowers body weight through distributed neural pathways. JCI Insight.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine.
Jastreboff AM, et al. Tirzepatide once weekly for obesity. New England Journal of Medicine.
le Roux CW, et al. Survodutide for obesity. New England Journal of Medicine. 2026.
Ji L, et al. Mazdutide in adults with obesity or overweight. New England Journal of Medicine. 2025.
Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity. New England Journal of Medicine.
Perkovic V, et al. Semaglutide and chronic kidney disease in type 2 diabetes. New England Journal of Medicine.
Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists. Lancet Diabetes & Endocrinology.
Heymsfield SB, Wadden TA. Mechanisms and management of obesity. New England Journal of Medicine.
Morton GJ, et al. Neurobiology of food intake. Nature Reviews Neuroscience.
Kenny PJ. Reward mechanisms in obesity. Neuron.
Hall KD, et al. Energy balance and body-weight regulation. American Journal of Clinical Nutrition.
Prado CMM, et al. Muscle mass and obesity pharmacotherapy. Lancet Diabetes & Endocrinology.
Rubino D, et al. Weight regain after withdrawal of semaglutide. Diabetes, Obesity and Metabolism.
Courcoulas AP, et al. Long-term outcomes of bariatric surgery. JAMA Surgery.
Rinella ME, et al. AASLD practice guidance for MASLD. Hepatology.
Younossi ZM, et al. Global burden of MASLD and MASH. Hepatology.
International Council for Harmonisation. ICH Q1A(R2): Stability Testing.
International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures.
International Council for Harmonisation. ICH Q3A and Q3B: Impurities.
International Council for Harmonisation. ICH Q3C: Residual Solvents.
International Council for Harmonisation. ICH Q6B: Specifications for Biotechnological Products.
International Council for Harmonisation. ICH M10: Bioanalytical Method Validation.
United States Pharmacopeia General Chapter <621>: Chromatography.
United States Pharmacopeia General Chapter <71>: Sterility Tests.
United States Pharmacopeia General Chapter <85>: Bacterial Endotoxins Test.
United States Pharmacopeia General Chapter <788>: Particulate Matter in Injections.

Chemistry, phase 2 and phase 3 obesity and diabetes findings, extension data, complication studies, safety, regulatory status, and analytical recommendations were reviewed in July 2026.

Post Views: 162